All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

EHA2022: What are the recent advances in MPN?

During the EHA 2022 Congress (EHA2022), the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, EHA2022: What are the recent advances in MPN?

EHA2022: What are the recent advances in MPN?

Kiladjian discusses some of the topics presented at EHA2022, including the results from the MANIFEST and MOMENTUM studies, and a new strategy to treat patients with CALR mutation, using a vaccine.